Reading this on a mobile device? Try our optimized mobile version here:

January 25, 2013News for medical technology professionals

  Top Story 
  • Myoscience gets FDA OK for handheld pain therapy device
    The FDA has cleared a next-generation version of myoscience's Focused Cold Therapy system for use in treating pain. The patented device, which administers cold therapy to targeted nerves, can be used to treat pain with no addictive potential or systemic side effects. (1/24) LinkedInFacebookTwitterEmail this Story
  Business & Market Trends 
  • Life Technologies boosts portfolio with BAC acquisition
    Life Technologies has agreed to pay an undisclosed fee to acquire BAC, a Dutch maker of protein purification tools. "Combining BAC's current portfolio and pipeline with our pre-existing portfolio expands Life's product offering and enables us to compete more fully across the protein purification market," said Tony Hunt, head of Life Technologies' BioProduction unit. GenomeWeb Daily News (free registration) (1/22) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • EU approves SPR's nerve stimulation device for chronic shoulder pain
    SPR Therapeutics has obtained CE mark approval to market its Smartpatch Peripheral Nerve Stimulation device in Europe. The technology, which can be used for a maximum of 30 days, uses peripheral nerve stimulation to treat chronic shoulder pain. The company also is pursuing FDA approval for use of the device in treating post-amputation and post-stroke pain. (1/24) LinkedInFacebookTwitterEmail this Story
  Science & Health 
  Emerging Technologies 
  • Argo launches updated version of exoskeleton technology
    Argo Medical has introduced ReWalk Rehabilitation 2.0, the latest version of the company's exoskeleton tailored for individuals with spinal cord injuries. The updated version, designed to fit a wider range of patients, comes with advanced sizing technology to prepare individuals for each session and a beginner mode to help new users adjust to the system. (1/24) LinkedInFacebookTwitterEmail this Story
  Industry Service Providers 
  • Texas facility joins R&D group for MRI radiotherapy device
    Philips Healthcare and Elekta have added MD Anderson Cancer Center to a research consortium for the development of technology that integrates MRI with radiation therapy. The hybrid technology is intended to allow doctors to adjust the delivery of radiation treatment in real time by giving them access to soft tissue and tumor images during the procedure. (free registration) (1/24) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • Senator urges action on final Sunshine Act regulations
    Sen. Chuck Grassley, R-Iowa, has asked the Obama administration to issue the long-awaited final rules on the Sunshine Act, saying the delays "are disrupting the considerable efforts of the pharmaceutical and medical device manufacturers that are already investing in systems to comply with the law." The law requires device and drug firms to report financial ties with doctors. (Boston) (1/24) LinkedInFacebookTwitterEmail this Story
  • FDA gives Varian Medical nod on 2 cancer therapy systems
    The FDA has given Varian Medical Systems 510(k) clearance for a new version of the company's Vitesse system, which allows doctors to plan high-dose-rate brachytherapy for prostate cancer patients in real time. The FDA also has cleared the company's Edge radiosurgery system, which comes with motion management and real-time tumor tracking tools. RTT News (1/24) LinkedInFacebookTwitterEmail this Story
AdvaMed News 
  • 510(k) Submissions Workshop
    Monday, Feb. 25 -- Tuesday, Feb. 26
    Sheraton Crystal City, Arlington, Va.
    Join quality and regulatory professionals at this interactive 510(k) workshop. Industry experts and key personnel from the FDA CDRH and CBER 510(k) staff inform you in detail on current FDA updates to the 510(k) process (eCopy Program for Medical Device Submissions); a step-by-step walk-through of the 510(k) regulatory guidelines; 510(k) practical steps and strategic considerations for determining a product's regulatory route to market; identifying a predicate device; planning and assembling a 510(k) submission; interacting with the FDA during the 510(k) review process; 510(k) post-clearance issues; and the Refuse to Accept Policy for 510(k)s.  Visit MTLI online for more information. LinkedInFacebookTwitterEmail this Story
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom

Position TitleCompany NameLocation
Neurovascular Intervention Marketing ManagerAsahi InteccSanta Ana, CA
Regional Service Manager PhilipsHartford, CT
Quality Systems ManagerRoche DiagnosticsIndianapolis, IN
Product Support Specialist IVArthroCare CorporationAustin, TX
Area Reimbursement Manager (Central U.S. or Northeast U.S.)SI-BONE, IncMultiple Locations, United States
Director of Clinical AffairsEndologixIrvine, CA
Sr. Clinical Research AssociateEndologix, Inc.Irvine, CA
Program Director, Regulatory AffairsJohnson & JohnsonFremont, CA
Click here to view more job listings.

  Editor's Note 
  • Correction
    A summary in the Jan. 23 AdvaMed SmartBrief incorrectly described DioGenix's MSPrecise test used to diagnose multiple sclerosis. The test measures cerebrospinal fluid. SmartBrief regrets the error. LinkedInFacebookTwitterEmail this Story
In youth we learn; in age we understand."
--Marie von Ebner-Eschenbach,
Austrian writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
A powerful website for SmartBrief readers including:
 Recent AdvaMed SmartBrief Issues:   Lead Editor:  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information